Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus

Journal of Translational Medicine

Adeeba Kamarulzaman²  Esaki M Shankar³  Reinhold E Schmidt¹  AW Wahid Ansari² 

[1] Department of Clinical Immunology and Rheumatology, Hannover Medical School, Carl-Neuberger Str.1, Hannover, D-30625, Germany;Department of Medicine, Faculty of Medicine, University of Malaya, Lambah Pantai 50603, Kuala Lumpur, Malaysia;Tropical Infectious Diseases Research and Education Centre, Faculty of Medicine, University of Malaya, Lambah Pantai 50603, Kuala Lumpur, Malaysia

关键词: Viral cross-talk;    Hepatic stellate cells;    Combination anti-retroviral therapy;    Inflammation;    C-C chemokine ligand-2;    Liver fibrosis;    Immuno-pathogenesis;    HIV/Hepatitis-C co-infection;   

Others  :  1146736
DOI  :  10.1186/s12967-014-0341-8

 received in 2014-10-03, accepted in 2014-11-24,  发布年份 2014

【 摘 要 】

Even in the era of successful combination antiretroviral therapy (cART), co-infection of Hepatitis C virus (HCV) remains one of the leading causes of non-AIDS-related mortality and morbidity among HIV-positive individuals as a consequence of accelerated liver fibrosis and end-stage liver disease (ESLD). The perturbed liver microenvironment and induction of host pro-inflammatory mediators in response to HIV and HCV infections, play a pivotal role in orchestrating the disease pathogenesis and clinical outcomes. How these viruses communicate each other via chemokine CCL2 and exploit the liver specific cellular environment to exacerbate liver fibrosis in HIV/HCV co-infection setting is a topic of intense discussion. Herein, we provide recent views and insights on potential mechanisms of CCL2 mediated immuno-pathogenesis, and HIV-HCV cross-talk in driving liver inflammation. We believe CCL2 may potentially serve an attractive target of anti-fibrotic intervention against HIV/HCV co-infection associated co-morbidities.

【 授权许可】

   
2014 Ansari et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rotman Y, Liang TJ: Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009, 83(15):7366-7374.
• [2]Hernandez MD, Sherman KE: HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011, 6(6):478-482.
• [3]Chen JY, Feeney ER, Chung RT: HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014, 11(6):362-371.
• [4]Sulkowski MS: Hepatitis C Virus Infection in HIV-infected Patients. Curr Infect Dis Rep 2001, 3(5):469-476.
• [5]Singal AK, Anand BS: Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009, 15(30):3713-3724.
• [6]Hernando V, Perez Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, Rubio R, Dalmau D, Moreno S, Amo JD: All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012, 57(4):743-751.
• [7]Rehermann B: Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013, 19(7):859-868.
• [8]Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, Moreno A, González-Serrano M, Iribarren JA, Ortega E, Miralles P, Mira JA, Pineda JA: Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009, 50(4):1056-1063.
• [9]Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, Euro SSG: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002.
• [10]Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M: Swiss HIV Cohort Study Group: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003, 163(18):2187-2195.
• [11]Miller MF, Haley C, Koziel MJ, Rowley CF: Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am 2005, 41(5):713-720.
• [12]Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000, 356(9244):1800-1805.
• [13]Rollins BJ: Chemokines. Blood 1997, 90(3):909-928.
• [14]Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2(2):123-128.
• [15]Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM: CCL2 blockade augments cancer immunotherapy. Cancer Res 2010, 70:109-118.
• [16]Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475(7355):222-225.
• [17]Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, Hashimoto K, Yamamoto M, Fujio H, Miura A, Ohta K, Morita H, Saito H, Emori T, Nakamura Y, Kusano I, Ohe T: Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J Off J Jpn Circ Soc 2004, 68(7):671-676.
• [18]Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S: Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008, 22:1433-1439.
• [19]Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, Purcell RH, Pybus OG, Alter HJ: Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A 2012, 109(36):14562-14567.
• [20]Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, Baeck C, Hittatiya K, Eulberg D, Luedde T, Kiessling F, Trautwein C, Lammers T, Tacke F. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.Gut, 63:1960-1971
• [21]Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, Hittatiya K, Eulberg D, Luedde T, Trautwein C, Tacke F: Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014, 59:1060-1072.
• [22]Marra F, Tacke F: Roles for chemokines in liver disease. Gastroenterology 2014, 114:577-594e572.
• [23]Hernandez Gea V, Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol 2011, 6:425-456.
• [24]Marra F, Aleffi S, Galastri S, Provenzano A: Mononuclear cells in liver fibrosis. Semin Immunopathol 2009, 31(3):345-358.
• [25]Schwabe RF, Seki E, Brenner DA: Toll-like receptor signaling in the liver. Gastroenterology 2006, 130(6):1886-1900.
• [26]Presser LD, McRae S, Waris G: Activation of TGF-beta1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-beta1 in hepatic stellate cell activation and invasion. PLoS One 2013, 8(2):e56367.
• [27]Huang F, Geng XP: Chemokines and hepatocellular carcinoma. World J Gastroenterol 2010, 16(15):1832-1836.
• [28]Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F: Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010, 5:e11049.
• [29]Ansari AW, Meyer-Olson D, Schmidt RE: Selective expansion of pro-inflammatory chemokine CCL2-loaded CD14 + CD16+ monocytes subset in HIV-infected therapy naive individuals. J Clin Immunol 2013, 33(1):302-306.
• [30]Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ, Pierce RH, Crispe IN: Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 2007, 110(12):4077-4085.
• [31]Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F: Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50(1):261-274.
• [32]Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR: HIV and co-infections. Immunol Rev 2013, 254(1):114-142.
• [33]Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, Ho DD: Identification and quantitation of HIV-1 in the liver of patients with AIDS. Aids 1992, 6(1):65-70.
• [34]Housset C, Boucher O, Girard PM, Leibowitch J, Saimot AG, Brechot C, Marche C: Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells. Hum Pathol 1990, 21(4):404-408.
• [35]Schmitt MP, Gendrault JL, Schweitzer C, Steffan AM, Beyer C, Royer C, Jaeck D, Pasquali JL, Kirn A, Aubertin AM: Permissivity of primary cultures of human Kupffer cells for HIV-1. AIDS Res Hum Retrovir 1990, 6(8):987-991.
• [36]Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, Chen P, Chen BK, Klotman ME, Bansal MB: Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010, 52(2):612-622.
• [37]Sengupta S, Powell E, Kong L, Blackard JT: Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One 2013, 8(6):e64956.
• [38]Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, Capitani S, La Placa M: Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994, 88(2):261-267.
• [39]Hu R, Oyaizu N, Than S, Kalyanaraman VS, Wang XP, Pahwa S: HIV-1 gp160 induces transforming growth factor-beta production in human PBMC. Clin Immunol Immunopathol 1996, 80(3 Pt 1):283-289.
• [40]Patel P, Khan N, Rani M, Gupta D, Jameel S: The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-beta that activates profibrogenic genes in hepatic stellate cells. PLoS One 2014, 9(2):e88934.
• [41]Qu J, Zhang Q, Li Y, Liu W, Chen L, Zhu Y, Wu J: The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol 2012, 13:15.
• [42]Balagopal A, Ray SC, De Oca RM, Sutcliffe CG, Vivekanandan P, Higgins Y, Mehta SH, Moore RD, Sulkowski MS, Thomas DL, Torbenson MS: Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009, 23:2397-2404.
• [43]Koziel MJ, Peters MG: Viral hepatitis in HIV infection. N Engl J Med 2007, 356(14):1445-1454.
• [44]Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377(9772):1198-1209.
• [45]Lin W, Weinberg EM, Chung RT: Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis 2013, 207(Suppl 1):S13-S18.
• [46]Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134(6):1655-1669.
• [47]Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, Milani S, Gessani S, Fantuzzi L, Liotta F, Frosali F, Antonucci G, Pinzani M, Marra F: gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010, 59(4):513-520.
• [48]Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY, Chung RT: Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010, 138(7):2509-2518. 2518 e2501
• [49]Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, Kim SS, Borges CB, Shao RX, Chung RT: HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008, 134(3):803-811.
• [50]Jang JY, Shao RX, Lin W, Weinberg E, Chung WJ, Tsai WL, Zhao H, Goto K, Zhang L, Mendez-Navarro J, Jilg N, Peng LF, Brockman MA, Chung RT: HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 2011, 54(4):612-620.
• [51]Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, Himmelsbach K, Carvajal-Yepes M, Huber R, Wakita T, Schmitt-Graeff A, Royer C, Blum HE, Fischer R, Baumert TF: Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol 2008, 181(7):4926-4935.
• [52]Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, Locarnini SA, Slavin J, Desmond PV, Lewin SR: Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. Aids 2011, 25(2):197-205.
• [53]Macias J, Japon MA, Saez C, Palacios RB, Mira JA, Garcia-Garcia JA, Merchante N, Vergara S, Lozano F, Gomez-Mateos J, Pineda JA: Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 2005, 192:1566-1576.
• [54]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12(12):1365-1371.
• [55]Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, Sebolao B, Tran A, Spelman T, Matthews G, Cameron P, Tangkijvanich P, Dore GJ, Ruxrungtham K, Lewin SR: Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. J Infect Dis 2014, 210(5):745-751.
• [56]Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC: Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011, 141:1220-1230. 1230 e1221-1223
• [57]Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA: Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003, 37(5):1043-1055.
• [58]Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13(11):1324-1332.
• [59]Crane M, Iser D, Lewin SR: Human immunodeficiency virus infection and the liver. World J Hepatol 2012, 4(3):91-98.
• [60]Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, Kirk GD, Mehta SH, Cox AL, Thomas DL, Ray SC: Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008, 135:226-233.
• [61]French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN: Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis 2013, 208(4):679-689.
• [62]Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A: CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008, 197(10):1402-1407.
• [63]Kovacs A, Karim R, Mack WJ, Xu J, Chen Z, Operskalski E, Frederick T, Landay A, Voris J, Spencer LS, Young MA, Tien PC, Augenbraun M, Strickler HD, Al-Harthi L: Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infectious Dis 2010, 201(6):823-834.
• [64]Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270(5243):1811-1815.
• [65]Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382(6594):829-833.
• [66]Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382(6594):833-835.
• [67]Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, Wells TN, Schlöndorff D, Proudfoot AE: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998, 187(8):1215-1224.
• [68]Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11(11):1170-1172.
• [69]Mengozzi M, De Filippi C, Transidico P, Biswas P, Cota M, Ghezzi S, Vicenzi E, Mantovani A, Sozzani S, Poli G: Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 1999, 93(6):1851-1857.
• [70]Ansari AW, Bhatnagar N, Dittrich-Breiholz O, Kracht M, Schmidt RE, Heiken H: Host chemokine (C-C motif) ligand-2 (CCL2) is differentially regulated in HIV type 1 (HIV-1)-infected individuals. Int Immunol 2006, 18(10):1443-1451.
• [71]Ansari AW, Schmidt RE, Heiken H: Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings. Clin Immunol 2007, 125(1):1-4.
• [72]Ansari AW, Heiken H, Meyer-Olson D, Schmidt RE: CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol 2011, 41(12):3412-3418.
• [73]Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, Transidico P, Vagani A, Sozzani S, Mantovani A, Lazzarin A, Poli G: Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Aids 1998, 12(11):1327-1332.
• [74]Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE: Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett 2007, 110(1):1-5.
• [75]Ansari AW, Kamarulzaman A, Schmidt RE: Multifaceted Impact of Host C-C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection. Front Immunol 2013, 4:312.
• [76]Campbell GR, Spector SA: CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem 2008, 283(45):30745-30753.
• [77]Jourdan P, Abbal C, Noraz N, Hori T, Uchiyama T, Vendrell JP, Bousquet J, Taylor N, Pene J, Yssel H: IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol 1998, 160(9):4153-4157.
• [78]Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404(6776):407-411.
• [79]Fantuzzi L, Spadaro F, Vallanti G, Canini I, Ramoni C, Vicenzi E, Belardelli F, Poli G, Gessani S: Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood 2003, 102(7):2334-2337.
• [80]Sui Y, Li S, Pinson D, Adany I, Li Z, Villinger F, Narayan O, Buch S: Simian human immunodeficiency virus-associated pneumonia correlates with increased expression of MCP-1, CXCL10, and viral RNA in the lungs of rhesus macaques. Am J Pathol 2005, 166(2):355-365.
• [81]Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugyenyi P, Mugerwa RD, Aung H, Ellner JJ, Hirsch CS: Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001, 28(1):1-8.
• [82]Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E: The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013, 2013:187204.
• [83]Van Sweringen HL, Sakai N, Quillin RC, Bailey J, Schuster R, Blanchard J, Goetzman H, Caldwell CC, Edwards MJ, Lentsch AB: Roles of hepatocyte and myeloid CXC chemokine receptor-2 in liver recovery and regeneration after ischemia/reperfusion in mice. Hepatology 2013, 57(1):331-338.
• [84]Teicher BA, Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16(11):2927-2931.
• [85]Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, Rice CM, Pol S, Albert ML: Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 2007, 204(10):2423-2437.
• [86]Matsuno K, Nomiyama H, Yoneyama H, Uwatoku R: Kupffer cell-mediated recruitment of dendritic cells to the liver crucial for a host defense. Dev Immunol 2002, 9(3):143-149.
• [87]Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, Marcellin P: Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129:2064-2075.
• [88]Zhdanov KV, Gusev DA, Chirskii VS, Sysoev KA, Iakubovskaia LA, Shakhmanov DM, Totolian AA: Chronic HCV-infection and expression of mRNA of CC-chemokines and their receptors]. Zh Mikrobiol Epidemiol Immunobiol 2008, 4:73-78.
• [89]Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z: Cytokine–chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007, 149(3):126-136.
• [90]Micheloud D, Salcedo M, Banares R, Rincon D, Lorente R, Munoz-Fernandez MA, Resino S: Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 2009, 11(2):183-188.
• [91]Yu DC, Chen J, Sun XT, Zhuang LY, Jiang CP, Ding YT: Mechanism of endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in hepatocellular carcinoma. BMC Cancer 2010, 10:435.
• [92]Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, Olthoff KM: Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 2012, 18(2):166-176.
• [93]Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K: Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 2013, 87(14):8169-8178.
• [94]Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115(2):209-218.
• [95]Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88(1):125-172.
• [96]Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, Schwabe RF, Brenner DA: CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50(1):185-197.
• [97]Harada K, Chiba M, Okamura A, Hsu M, Sato Y, Igarashi S, Ren XS, Ikeda H, Ohta H, Kasashima S, Kawashima A, Nakanuma Y: Monocyte chemoattractant protein-1 derived from biliary innate immunity contributes to hepatic fibrogenesis. J Clin Pathol 2011, 64(8):660-665.
• [98]Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA: Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005, 280(45):37481-37488.
• [99]Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J, Hellerbrand C: A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125(4):1085-1093.
• [100]Rockstroh JK, Bhagani S: Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med 2013, 11:234.
• [101]Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A: EuroSIDA in EuroCoord: Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013, 14(10):614-623.
• [102]Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W: P05411 study investigators: Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013, 13(7):597-605.
• [103]Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V: Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013, 159(2):86-96.